nCage Therapeutics to collaborate with the University of Nottingham on a novel Chagas vaccine

Kraków: nCage Therapeutics announced today that it had recently completed a collaboration agreement with the University of Nottingham in the United Kingdom, to develop a first-in-class Chagas vaccine.

nCage Chief Executive Officer and President of the Management Board, Dr. John Bason, noted: “We are extremely pleased to collaborate with a global Chagas research leader at Nottingham University. Chagas is an unmet need in many countries in Latin America, and an effective vaccine would be a significant step in providing better health outcomes to many patients. We hope to progress towards a clinical candidate in the coming years.”